ResearcherChinese University of Hong KongActive in the last 2 years

Yulin Wu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112522896. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2025: 1 paper

Papers 1

20(S)-Ginsenoside Rh2 overcomes gemcitabine resistance in pancreatic cancer by inhibiting LAMC2-Modulated ABC transporters. Co-author DOI 10.1016/j.jare.2024.09.006 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hong‐Xi Xu · 1 shared paper, 2025 · strength 0.28
- Paper 20(S)-Ginsenoside Rh2 overcomes gemcitabine resistance in pancreatic cancer by inhibiting LAMC2-Modulated ABC transport… DOI 10.1016/j.jare.2024.09.006 ↗
Yan‐Fang Xian · 1 shared paper, 2025 · strength 0.28
- Paper 20(S)-Ginsenoside Rh2 overcomes gemcitabine resistance in pancreatic cancer by inhibiting LAMC2-Modulated ABC transport… DOI 10.1016/j.jare.2024.09.006 ↗
Juan Zhang · 1 shared paper, 2025 · strength 0.28
- Paper 20(S)-Ginsenoside Rh2 overcomes gemcitabine resistance in pancreatic cancer by inhibiting LAMC2-Modulated ABC transport… DOI 10.1016/j.jare.2024.09.006 ↗
Zhi‐Xiu Lin · 1 shared paper, 2025 · strength 0.28
- Paper 20(S)-Ginsenoside Rh2 overcomes gemcitabine resistance in pancreatic cancer by inhibiting LAMC2-Modulated ABC transport… DOI 10.1016/j.jare.2024.09.006 ↗
William Chi Shing Cho · 1 shared paper, 2025 · strength 0.28
- Paper 20(S)-Ginsenoside Rh2 overcomes gemcitabine resistance in pancreatic cancer by inhibiting LAMC2-Modulated ABC transport… DOI 10.1016/j.jare.2024.09.006 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.